Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
CRXT was delisted on the 30th of August, 2022.
12 hedge funds and large institutions have $12.1M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 30 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
64% less funds holding
Funds holding: 33 → 12 (-21)
70% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 30
76% less capital invested
Capital invested by funds: $51M → $12.1M (-$39M)
77.77% less ownership
Funds ownership: 87.18% → 9.41% (-78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCL
Bracebridge Capital LLC
Boston,
Massachusetts
|
+$18M |
| 2 |
TI
Telemetry Investments
New York
|
+$405K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$390K |
| 4 |
PIA
Powell Investment Advisors
Miami,
Florida
|
+$387K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$320K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$7.76M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$4.13M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$4.03M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.88M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.77M |
CRXT Hedge Fund Activity: Q3 2021 in Review
12 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q3 2021, worth a combined $12.1M — down 76% from $51M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of CRXT and 9 opened new positions — a net loss of 21 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Bracebridge Capital LLC, opening a new position worth an estimated $18M. The largest seller was Karpus Investment Management, exiting entirely with an estimated $7.76M sold.
- 12 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q3 2021, down from 33 in Q2 2021.
- Funds reported $12.1M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q3 2021, down 76% quarter-over-quarter.
- 9 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q3 2021 and 30 closed out, a net change of -21 holders.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q3 2021 was Bracebridge Capital LLC, an estimated $18M added.
- The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q3 2021 was Karpus Investment Management, an estimated $7.76M sold.
Based on aggregated 13F filings for Q3 2021.